- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Oruka's psoriasis data hailed as 'outright win over Skyrizi,' spurring big blockbuster forecasts | ||
| Mo | Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint 'compelling' picture | ||
| Mo | Lilly maintains M&A hot streak with $2.3B deal for next-gen JAK inhibitor biotech Ajax | ||
| Mo | British biotech VC funding shows 'signs of recovery,' but IPO rebound yet to materialize | ||
| 24.04. | Compass, Usona score FDA national priority vouchers amid Trump administration's psychedelic push | ||
| 24.04. | After Lilly's $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy? | ||
| 24.04. | Chutes & Ladders-Helus shuffles out CEO after two months, adds experience to science board | ||
| 24.04. | Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs | ||
| 23.04. | Pfizer cans work on next-gen conjugate in cancer patients | ||
| 23.04. | From debt to 'acceptable' prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree | ||
| 23.04. | Sanofi interim CEO defends Hudson's Dupixent legacy, but accepts 'number of setbacks' | ||
| 22.04. | Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors | ||
| 21.04. | Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia | ||
| 21.04. | Ray Therapeutics shines a light on $125M round targeting genetic eye therapy | ||
| 21.04. | Gilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure | ||
| 20.04. | AACR: Endeavoring to go global, Zai Lab offers reality check on China's biotech ascent | ||
| 20.04. | Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody | ||
| 20.04. | Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B | ||
| 20.04. | Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win | ||
| 20.04. | AstraZeneca's faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win | ||
| 20.04. | Odyssey charts fresh voyage to public markets after abandoning IPO plans last year | ||
| 20.04. | Agenus focuses on survival data as 0% response rate triggers primary miss | ||
| 20.04. | Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster | ||
| 17.04. | Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans | ||
| 17.04. | UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.